Patient information: uses, side effects, how to take - Nucala
What is NUCALA?
NUCALA is a prescription medicine:
for the add-on maintenance treatment of severe asthma in people 6 years of age and older whose asthma is not controlled with their current asthma medicines. NUCALA helps prevent severe asthma attacks (exacerbations).
NUCALA is not used to treat sudden breathing problems that occur with asthma.
- for add-on maintenance treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) in adults whose disease is not controlled with nasal corticosteroids. NUCALA helps reduce symptoms (e.g., nasal congestion, nasal discharge, mucus in the throat, loss of smell). NUCALA helps reduce the size of your nasal polyps and the use of oral corticosteroid medicines. NUCALA helps prevent surgery for your nasal polyps.
for add-on maintenance treatment of chronic obstructive pulmonary disease (COPD) in adults whose disease is not controlled and who are at risk of flare-ups and increasing symptoms. NUCALA helps prevent flare-ups of COPD symptoms (exacerbations).
NUCALA is not used to treat sudden breathing problems that can occur with COPD.
- for the treatment of adults with eosinophilic granulomatosis with polyangiitis (EGPA). NUCALA helps reduce symptoms and flares, and it may allow your healthcare provider to reduce your oral corticosteroid medicine.
- for the treatment of people 12 years of age and older with hypereosinophilic syndrome (HES) for 6 months or more. NUCALA helps reduce symptoms and prevent flares.
- NUCALA works by targeting inflammation that plays a major role in severe asthma, CRSwNP, COPD, EGPA and HES. NUCALA reduces blood eosinophils. Eosinophils are a type of white blood cells that may contribute to your disease.
It is not known if NUCALA is safe and effective in:
children with severe asthma under 6 years of age.
- children and adolescents with CRSwNP, COPD or EGPA under 18 years of age; or
- children with HES under 12 years of age.
Do not use NUCALA if you are allergic to mepolizumab or any of the ingredients in NUCALA. See the end of this leaflet for a complete list of ingredients in NUCALA.
Before receiving NUCALA, tell your healthcare provider about all of your medical conditions, including if you:
- have a parasitic (helminth) infection.
- are taking oral or inhaled corticosteroid medicines. Do not stop taking your corticosteroid medicines unless instructed by your healthcare provider. This may cause other symptoms that were controlled by the corticosteroid medicine to come back.
are pregnant or plan to become pregnant. It is not known if NUCALA may harm your unborn baby.
- are breastfeeding or plan to breastfeed. You and your healthcare provider should decide if you will use NUCALA and breastfeed. You should not do both without talking with your healthcare provider first.
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
- Do not stop taking your other medicines unless instructed to do so by your healthcare provider.
How will I receive NUCALA?
Your healthcare provider will prescribe the dose that is right for you depending on what you are being treated for.
When injection is given by a healthcare provider:
- A healthcare provider will inject NUCALA under your skin (subcutaneously) every 4 weeks.
When injection is given by a patient or patient caregiver with a prefilled syringe or prefilled autoinjector:
- NUCALA may be prescribed as a single-dose prefilled autoinjector for people 12 years of age and older or as a single-dose prefilled syringe for people 6 years of age and older.
- Use NUCALA every 4 weeks exactly as your healthcare provider tells you to.
- Before you use NUCALA, your healthcare provider will show you or your caregiver how to give the injections.
- Read the Instructions for Use that comes with NUCALA for instructions about the right way to give your injections at home.
- You should inject NUCALA under your skin (subcutaneously) into your thigh or stomach (abdomen). Also, a caregiver may give the injection in the upper arm.
- If you miss a dose, inject a dose as soon as possible. Then continue (resume) your injection on your regular dosing schedule. If you do not notice that you have missed a dose until it is time for your next scheduled dose, then inject the next scheduled dose as planned. If you are not sure when to inject NUCALA, call your healthcare provider.
What are the possible side effects of NUCALA?
NUCALA can cause serious side effects, including:
- allergic (hypersensitivity) reactions, including anaphylaxis. Serious allergic reactions can happen after you get your NUCALA injection. Allergic reactions can sometimes happen hours or days after you get a dose of NUCALA. Tell your healthcare provider or get emergency help right away if you have any of the following symptoms of an allergic reaction:
- swelling of your face, mouth, and tongue
- fainting, dizziness, feeling lightheaded (low blood pressure)
- hives
- breathing problems
- rash
- herpes zoster infections. Herpes zoster infections that can cause shingles have happened in people who received NUCALA.
The most common side effects of NUCALA include: headache, injection site reactions (pain, redness, swelling, itching, or a burning feeling at the injection site), back pain, and tiredness (fatigue). Mouth/throat pain and joint pain have been reported with CRSwNP. Diarrhea and cough have been reported with COPD.
These are not all of the possible side effects of NUCALA.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
How should I store NUCALA?
- Store prefilled autoinjectors and prefilled syringes in the refrigerator between 36°F to 46°F (2°C to 8°C).
- Keep prefilled autoinjectors and prefilled syringes in the original carton until time of use to protect from light.
- Do not freeze. Do not shake. Keep away from heat.
- If necessary, an unopened carton can be stored outside the refrigerator at up to 86°F (30°C) for up to 7 days.
- Safely throw away prefilled autoinjectors and prefilled syringes if the unopened carton is left out of the refrigerator for more than 7 days.
- Prefilled autoinjectors and prefilled syringes must be used within 8 hours after you take them out of the carton. Safely throw away if not used within 8 hours.
- Safely throw away medicine that is out of date or no longer needed.
Keep NUCALA and all medicines out of the reach of children.
General information about the safe and effective use of NUCALA.
Medicines are sometimes prescribed for purposes other than those listed in a Patient Information Leaflet. Do not give NUCALA to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about NUCALA that is written for health professionals.
What are the ingredients in NUCALA?
Active Ingredient: mepolizumab.
Inactive Ingredients (vials): polysorbate 80, sodium phosphate dibasic heptahydrate, and sucrose.
Inactive Ingredients (prefilled autoinjectors and prefilled syringes): citric acid monohydrate, EDTA disodium dihydrate, polysorbate 80, sodium phosphate dibasic heptahydrate, and sucrose.
For more information about NUCALA, call 1-888-825-5249 or visit our website at www.NUCALA.com.
Trademarks are owned by or licensed to the GSK group of companies.
Manufactured by:
GlaxoSmithKline LLC, Philadelphia, PA 19104, U.S. License No. 1727
Distributed by:
GlaxoSmithKline, Durham, NC 27701
©2025 GSK group of companies or its licensor.
NCL:10PIL
- This Patient Information has been approved by the U.S. Food and Drug Administration. Revised: May 2025
| Instructions for Use |
NUCALA (mepolizumab) injection, for subcutaneous use 100 mg/mL Prefilled Autoinjector |
| Important information |
NUCALA is a prescription medicine that is injected under the skin (subcutaneous) from a single-dose prefilled autoinjector. You and your caregiver should be trained on how to prepare and perform your injection before trying to do it yourself. The following instructions provide the information you need to correctly use the prefilled autoinjector with yellow needle guard. Before starting your injection, it is important that you read and understand these instructions and then carefully follow them so that you complete each step successfully. |
| Storage information |
Keep NUCALA and all medicines out of the reach of children. |
| Warnings |
|
| Know your prefilled autoinjector |
![]() |
| Supplies in carton |
| 1 Prefilled autoinjector |
| Supplies not in carton |
|
| Prepare |
|
![]() |
|
|
![]() |
|
|
![]() |
|
|
![]() |
|
| Inject |
|
![]() |
|
|
![]() |
|
|
![]() |
|
| Dispose |
|
![]() |
Put your used autoinjector and clear needle cap in an FDA-cleared sharps disposal container right away after use. If you do not have an FDA-cleared sharps disposal container, you may use a household container that is:
When your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of it. There may be state or local laws about how you should throw away used autoinjectors. For more information about safe sharps disposal, and for specific information about sharps disposal in the state that you live in, go to the FDA’s website at: www.fda.gov/safesharpsdisposal.
Keep your sharps disposal container out of the reach of children. |
| Frequently asked questions |
For more information about NUCALA, call 1-888-825-5249 or visit our website at www.NUCALA.com. Trademarks are owned by or licensed to the GSK group of companies. Manufactured by: GlaxoSmithKline LLC, Philadelphia, PA 19104, U.S. License No. 1727 Distributed by: GlaxoSmithKline, Durham, NC 27701 ©2023 GSK group of companies or its licensor. NCL:4IFU-A This Instructions for Use has been approved by the U.S. Food and Drug Administration. Revised: March 2023 |
| Instructions for Use |
NUCALA (mepolizumab) injection, for subcutaneous use 100 mg/mL Prefilled Syringe |
| Important information |
NUCALA is a prescription medicine that is injected under the skin (subcutaneous) from a single-dose prefilled syringe. You and your caregiver should be trained on how to prepare and perform your injection before trying to do it yourself. The following instructions provide the information you need to correctly use the prefilled syringe with automatic needle guard. Before starting your injection, it is important that you read and understand these instructions and then carefully follow them so that you complete each step successfully. |
| Storage information |
Keep NUCALA and all medicines out of the reach of children. |
| Warnings |
|
| Know your prefilled syringe |
![]() |
| Supplies in carton |
| 1 Prefilled syringe |
| Supplies not in carton |
|
| Prepare |
|
![]() |
|
|
![]() |
|
|
![]() |
|
|
![]() |
|
| Inject |
|
![]() |
|
|
![]() |
|
|
![]() |
|
| Dispose |
|
![]() |
Put your used syringe and gray needle cap in an FDA-cleared sharps disposal container right away after use. If you do not have an FDA-cleared sharps disposal container, you may use a household container that is:
When your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of it. There may be state or local laws about how you should throw away used syringes. For more information about safe sharps disposal, and for specific information about sharps disposal in the state that you live in, go to the FDA’s website at: www.fda.gov/safesharpsdisposal.
Keep your sharps disposal container out of the reach of children. |
| Frequently asked questions |
For more information about NUCALA, call 1-888-825-5249 or visit our website at www.NUCALA.com. Trademarks are owned by or licensed to the GSK group of companies. Manufactured by: GlaxoSmithKline LLC, Philadelphia, PA 19104, U.S. License No. 1727 Distributed by: GlaxoSmithKline, Durham, NC 27701 ©2023 GSK group of companies or its licensor. NCL:4IFU-S This Instructions for Use has been approved by the U.S. Food and Drug Administration. Revised: March 2023 |
| Instructions for Use |
NUCALA (mepolizumab) injection, for subcutaneous use 40 mg/0.4 mL Prefilled Syringe |
| Important information |
NUCALA is a prescription medicine that is injected under the skin (subcutaneous) from a single-dose prefilled syringe. You should be trained on how to prepare and perform the injection before trying to do it yourself. The following instructions provide the information you need to correctly use the prefilled syringe with automatic needle guard. Before starting the injection, it is important that you read and understand these instructions and then carefully follow them so that you complete each step successfully. |
| Storage information |
Keep NUCALA and all medicines out of the reach of children. |
| Warnings |
|
| Know the prefilled syringe |
![]() |
| Supplies in carton |
| 1 Prefilled syringe |
| Supplies not in carton |
|
| Prepare |
|
![]() |
|
|
![]() |
|
|
![]() |
|
|
![]() |
|
| Inject |
|
![]() |
|
|
![]() |
|
|
![]() |
|
| Dispose |
|
![]() |
Put the used syringe and gray needle cap in an FDA-cleared sharps disposal container right away after use. If you do not have an FDA-cleared sharps disposal container, you may use a household container that is:
When the sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of it. There may be state or local laws about how you should throw away used syringes. For more information about safe sharps disposal, and for specific information about sharps disposal in the state that you live in, go to the FDA’s website at: www.fda.gov/safesharpsdisposal.
Keep the sharps disposal container out of the reach of children. |
| Frequently asked questions |
For more information about NUCALA, call 1-888-825-5249 or visit our website at www.NUCALA.com. Trademarks are owned by or licensed to the GSK group of companies. Manufactured by: GlaxoSmithKline LLC, Philadelphia, PA 19104, U.S. License No. 1727 Distributed by: GlaxoSmithKline, Durham, NC 27701 ©2023 GSK group of companies or its licensor. NCL:2IFU-S40 This Instructions for Use has been approved by the U.S. Food and Drug Administration. Revised: March 2023 |


























